Delaware-based pharmaceutical company Incyte Corporation announced Saturday that its investigational medication povorcitinib delivered sustained improvement for patients suffering from a debilitating chronic skin condition in two advanced clinical studies.
The experimental treatment was evaluated in individuals diagnosed with moderate to severe hidradenitis suppurativa, a persistent skin disorder characterized by painful bumps, infected pockets, and permanent scarring that typically develops in body areas where skin contacts skin, such as underarms and the groin region.
Fresh clinical data presented at a recent medical conference revealed that following 54 weeks of therapy, as many as 71.4% of study participants receiving the medication experienced at least a 50% decrease in infected pockets and inflamed skin bumps during the research trials.
The research findings additionally demonstrated that as many as 57% of participants achieved significant symptom improvement, while up to 29% experienced total elimination of primary skin lesions.
Povorcitinib functions as a daily oral medication that operates by inhibiting JAK1, a specific protein that contributes to the inflammatory processes responsible for creating painful infected pockets and skin nodules.
Current therapeutic alternatives for this medical condition remain restricted and primarily consist of injection-based medications.
Presently, three FDA-authorized therapies exist for treating this disorder: AbbVie’s Humira, Novartis’ Cosentyx, and UCB’s Bimzelx.
According to Incyte, the most commonly reported adverse reactions included acne breakouts, throat and nasal inflammation, and upper respiratory system infections.
The U.S. Food and Drug Administration reports that hidradenitis suppurativa impacts approximately 1% to 4% of the American population, with disproportionately higher rates affecting individuals from racial and ethnic minority communities.
Incyte stated that regulatory submissions requesting povorcitinib approval are presently being evaluated by both the FDA and the European Medicines Agency.
